Country: Australia
Language: English
Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)
PORCINE CIRCOVIRUS TYPE 2 ORF2 SUBUNIT ANTIGEN
INTERVET AUSTRALIA PTY LIMITED
MISC. VACCINES OR ANTI SERA
PORCINE CIRCOVIRUS TYPE 2 ORF2 SUBUNIT ANTIGEN VACCINE-VIRAL Active 7180.0 AU/mL
10x10mL; 10x20mL; 1x10mL; 1x20mL
VM - Veterinary Medicine
IMMUNOTHERAPY
Poison schedule: 0; Withholding period: Zero (0) days.; Host/pest details: PIGS: [PREVENTING WEIGHT LOSS, PREVENTION OF PORCINE CIRCOVIRUS TYPE 2, REDUCTION OF PCV2 VIRAEMIA]
Registered
2023-07-01
Product Name: APVMA Approval No: PORCILIS PCV IDAL EMULSION FOR INJECTION FOR PIGS 84901/111721 Label Name: PORCILIS PCV IDAL EMULSION FOR INJECTION FOR PIGS Signal Headings: FOR ANIMAL TREATMENT ONLY Constituent Statements: Each dose of 0.2 mL contains: Active Constituent: Porcine circovirus type 2 (PCV2) ORF 2 subunit antigen: ≥ 1436 AU Claims: For the active immunisation of pigs against PCV2 infection. To reduce PCV2 associated viraemia, virus load in lungs, tonsils and lymphoid tissues. To reduce shedding caused by PCV2 infection, and thereby minimise environmental contamination. To reduce weight loss and mortality associated with PCV2 infection. Onset of immunity: 2 weeks after vaccination. Duration of immunity: 23 weeks after vaccination. Porcilis PCV IDAL is effective in the presence of maternally derived antibodies to PCV2. Net Contents: 1 x 10 mL 1 x 20 mL 10 x 10 mL 10 x 20 mL Directions for Use: READ THE ENCLOSED LEAFLET FOR FULL INSTRUCTIONS. SHAKE WELL BEFORE USE Use the entire contents within 8 hours of opening. Restraints: DO NOT mix with any other veterinary medicinal product. Contraindications: Precautions: Vaccinate healthy animals only. Safety studies to support the use of the product in breeding animals and pregnant females have not been conducted. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. RLP APPROVED Side Effects: Transient local reactions are common and usually consist of a hard non-painful swelling of up to 2 cm diameter. Occasionally the swellings may increase up to 4 cm diameter and may be associated with redness. The swellings may recur after initially subsiding and will disappear completely within approximately 5 weeks. Dosage and Administration: Before use allow the vaccine to reach room temperature. Shake well before use. FOR INTRADERMAL USE ONLY. Intradermal admi Read the complete document